CN1256980C - Medicine for treating cholecystitis - Google Patents
Medicine for treating cholecystitis Download PDFInfo
- Publication number
- CN1256980C CN1256980C CN 200310107689 CN200310107689A CN1256980C CN 1256980 C CN1256980 C CN 1256980C CN 200310107689 CN200310107689 CN 200310107689 CN 200310107689 A CN200310107689 A CN 200310107689A CN 1256980 C CN1256980 C CN 1256980C
- Authority
- CN
- China
- Prior art keywords
- radix
- medicine
- present
- radix paeoniae
- cholecystitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 36
- 201000001352 cholecystitis Diseases 0.000 title claims abstract description 25
- 229940079593 drug Drugs 0.000 title claims description 13
- 241000218176 Corydalis Species 0.000 claims abstract description 24
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 16
- 238000011282 treatment Methods 0.000 claims description 34
- 239000010135 fructus aurantii immaturus Substances 0.000 claims description 14
- 239000000796 flavoring agent Substances 0.000 claims description 3
- 235000019634 flavors Nutrition 0.000 claims description 3
- 208000002193 Pain Diseases 0.000 abstract description 16
- 230000036407 pain Effects 0.000 abstract description 16
- 206010008617 Cholecystitis chronic Diseases 0.000 abstract description 12
- 210000004369 blood Anatomy 0.000 abstract description 12
- 239000008280 blood Substances 0.000 abstract description 12
- 208000019790 abdominal distention Diseases 0.000 abstract description 7
- 238000002360 preparation method Methods 0.000 abstract description 7
- 210000001015 abdomen Anatomy 0.000 abstract description 6
- 210000000232 gallbladder Anatomy 0.000 abstract description 6
- 210000002784 stomach Anatomy 0.000 abstract description 5
- 241000612166 Lysimachia Species 0.000 abstract description 4
- 230000036528 appetite Effects 0.000 abstract description 4
- 235000019789 appetite Nutrition 0.000 abstract description 4
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 4
- 206010000060 Abdominal distension Diseases 0.000 abstract description 3
- 235000014375 Curcuma Nutrition 0.000 abstract description 3
- 206010067482 No adverse event Diseases 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 3
- 230000006870 function Effects 0.000 abstract description 3
- 210000004185 liver Anatomy 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 206010028813 Nausea Diseases 0.000 abstract description 2
- 208000005392 Spasm Diseases 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 230000008693 nausea Effects 0.000 abstract description 2
- 241000202726 Bupleurum Species 0.000 abstract 1
- 244000164480 Curcuma aromatica Species 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 241000736199 Paeonia Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 240000005001 Paeonia suffruticosa Species 0.000 abstract 1
- 235000003889 Paeonia suffruticosa Nutrition 0.000 abstract 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 13
- 239000000047 product Substances 0.000 description 12
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 230000006872 improvement Effects 0.000 description 7
- 208000011580 syndromic disease Diseases 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 5
- 238000002604 ultrasonography Methods 0.000 description 5
- 235000019658 bitter taste Nutrition 0.000 description 4
- 206010061428 decreased appetite Diseases 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 241000202807 Glycyrrhiza Species 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000006837 decompression Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000004064 recycling Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 206010006784 Burning sensation Diseases 0.000 description 2
- 241000407170 Curcuma Species 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000000197 Acute Cholecystitis Diseases 0.000 description 1
- 206010008614 Cholecystitis acute Diseases 0.000 description 1
- 206010062631 Cholecystitis infective Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 208000002513 Flank pain Diseases 0.000 description 1
- 208000037768 Gallbladder perforation Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 240000004859 Gamochaeta purpurea Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 238000009592 kidney function test Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 239000013588 oral product Substances 0.000 description 1
- 229940023486 oral product Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 238000009527 percussion Methods 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 201000010304 suppurative cholangitis Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to medicine for treating cholecystitis, which belongs to medicine. At present, the medicine for treating the cholecystitis has high production cost. The present invention is prepared from components of the following part by weight: 230 to 270 of bupleurum root, 230 to 270 of radix paeoniae alba, 230 to 270 of red peony root, 230 to 270 of curcuma root, 230 to 270 of toosendan fruit, 180 to 220 of lysimachia, 140 to 180 of corydalis tuber, 100 to 140 of tree peony bark, 140 to 180 of aurantii immaturus and 70 to 110 of liquorice. The product of the present invention has the advantages of easy raw material obtaining, low cost, simple preparation process and easy operation. The product has the functions of promoting the liver and the gallbladder, regulating qi and blood and relieving spasm and pains, and can be used for promoting qi stagnation and blood stasis and improving hypochondriac pains, poor appetite, glowing stomachs, heat qi, nausea, abdominal distention discomfort, distention and fullness of the gastric cavity and abdomen, etc. which are caused by damp-heat interior chronic cholecystitis. The present invention has the advantages of good therapeutic effect and no adverse reaction.
Description
Technical field: the present invention relates to a kind of medicine.
Background technology: now, the research document of relevant treatment cholecystitis medicine has had report, have plenty of with Fel Sus domestica, Semen phaseoli radiati and some Chinese medicine and make, have plenty of by Fel Gallus domesticus and Medulla Leporis seu Oryctolagi extract and form, through concentrate, organic solvent handles and is refined into, having plenty of with the Fel Bovis seu Bubali is primary raw material, and is equipped with Chinese medicines such as Radix Bupleuri, Radix Curcumae, Rhizoma Polygoni Cuspidati, the Radix Paeoniae Alba, Endothelium Corneum Gigeriae Galli, the Rhizoma Atractylodis Macrocephalae and makes, because the raw materials used certain limitation that is subjected to of medicine of existing treatment cholecystitis is so just increased production cost.
Summary of the invention: the medicine that the object of the present invention is to provide the treatment cholecystitis that a kind of raw material is easy to get, it is to be prepared from by Radix Bupleuri, the Radix Paeoniae Alba, Radix Paeoniae Rubra, Radix Curcumae, Fructus Toosendan, Herba Lysimachiae, Rhizoma Corydalis, Cortex Moutan, Fructus Aurantii Immaturus, Radix Glycyrrhizae ten flavor medicines, and the shared parts by weight of each component are: Radix Bupleuri 230～270, the Radix Paeoniae Alba 230～270, Radix Paeoniae Rubra 230～270, Radix Curcumae 230～270, Fructus Toosendan 230～270, Herba Lysimachiae 180～220, Rhizoma Corydalis 140～180, Cortex Moutan 100～140, Fructus Aurantii Immaturus 140～180, Radix Glycyrrhizae 70～110.Its preparation method is: the Rhizoma Corydalis of 230～270 parts Radix Curcumaes and 140～180 parts is respectively got half, and it is standby to be ground into fine powder; Remaining Radix Curcumae, Rhizoma Corydalis and 230～270 parts of Radix Bupleuri, 230～270 portions of Radix Paeoniae Albas, 230～270 parts of Radix Paeoniae Rubra, 230～270 parts of Fructus Toosendans, 180～220 portions of Herba Lysimachiaes, 100～140 parts of Cortex Moutans, 140～180 parts of Fructus Aurantii Immaturuss, 70～110 portions of Radix Glycyrrhizaes mix, decoct with water twice, adding the decocting that accounts for 10 times of amounts of all drug weight for the first time boiled 2 hours, the decocting that adds for the second time 8 times of amounts of all drug weight boiled 2 hours, collecting decoction, filter, relative density 1.10 when being concentrated into 80 ℃, slowly adding ethanol under stirring makes determining alcohol reach 45%, left standstill 12 hours, get supernatant, decompression recycling ethanol, and the clear paste of the relative density 1.38～1.40 when being concentrated into 80 ℃, add Radix Curcumae, the Rhizoma Corydalis fine powder, mixing, vacuum drying is ground into fine powder promptly.Products material of the present invention is easy to get, and is with low cost, and preparation method is simple, operation easily, the product 'Shugan Lidan ' is transferred smooth QI and blood, relieving spasm to stop pain can be used for qi depression to blood stasis, the caused hypochondriac pain of retention of damp-heat in the interior type chronic cholecystitis, inappetence, stomach is scorching hot, and dim gas is felt sick, the abdominal distention discomfort, the improvement of symptoms such as gastral cavity abdomen feeling of fullness, therapeutic effect of the present invention is good, has no adverse reaction.
The specific embodiment one: present embodiment is made up of Radix Bupleuri, the Radix Paeoniae Alba, Radix Paeoniae Rubra, Radix Curcumae, Fructus Toosendan, Herba Lysimachiae, Rhizoma Corydalis, Cortex Moutan, Fructus Aurantii Immaturus, Radix Glycyrrhizae ten flavor medicines, and the shared parts by weight of each component are: Radix Bupleuri 230～270, the Radix Paeoniae Alba 230～270, Radix Paeoniae Rubra 230～270, Radix Curcumae 230～270, Fructus Toosendan 230～270, Herba Lysimachiae 180～220, Rhizoma Corydalis 140～180, Cortex Moutan 100～140, Fructus Aurantii Immaturus 140～180, Radix Glycyrrhizae 70～110.Its preparation method is: the Rhizoma Corydalis of 230～270 parts Radix Curcumaes and 140～180 parts is respectively got half, and it is standby to be ground into fine powder; Remaining Radix Curcumae, Rhizoma Corydalis and 230～270 parts of Radix Bupleuri, 230～270 portions of Radix Paeoniae Albas, 230～270 parts of Radix Paeoniae Rubra, 230～270 parts of Fructus Toosendans, 180～220 portions of Herba Lysimachiaes, 100～140 parts of Cortex Moutans, 140～180 parts of Fructus Aurantii Immaturuss, 70～110 portions of Radix Glycyrrhizaes mix, decoct with water twice, adding the decocting that accounts for 10 times of amounts of all drug weight for the first time boiled 2 hours, the decocting that adds for the second time 8 times of amounts of all drug weight boiled 2 hours, collecting decoction, filter, relative density 1.10 when being concentrated into 80 ℃, slowly adding ethanol under stirring makes determining alcohol reach 45%, left standstill 12 hours, get supernatant, decompression recycling ethanol, and the clear paste of the relative density 1.38～1.40 when being concentrated into 80 ℃, add Radix Curcumae, the Rhizoma Corydalis fine powder, mixing, vacuum drying is ground into fine powder promptly.
The specific embodiment two: what present embodiment and the specific embodiment one were different is that the shared parts by weight of each component are: Radix Bupleuri 235～265, the Radix Paeoniae Alba 235～265, Radix Paeoniae Rubra 235～265, Radix Curcumae 235～265, Fructus Toosendan 235～265, Herba Lysimachiae 185～215, Rhizoma Corydalis 145～175, Cortex Moutan 105～135, Fructus Aurantii Immaturus 145～175, Radix Glycyrrhizae 75～105.Its preparation method is identical with the specific embodiment one.
The specific embodiment three: the shared parts by weight of each component are in the present embodiment: Radix Bupleuri 240～260, the Radix Paeoniae Alba 240～260, Radix Paeoniae Rubra 240～260, Radix Curcumae 240～260, Fructus Toosendan 240～260, Herba Lysimachiae 190～210, Rhizoma Corydalis 140～170, Cortex Moutan 100～130, Fructus Aurantii Immaturus 140～170, Radix Glycyrrhizae 70～100.
The specific embodiment four: the shared parts by weight of each component are in the present embodiment: Radix Bupleuri 245～255, the Radix Paeoniae Alba 245～255, Radix Paeoniae Rubra 245～255, Radix Curcumae 245～255, Fructus Toosendan 245～255, Herba Lysimachiae 195～205, Rhizoma Corydalis 150～165, Cortex Moutan 110～129, Fructus Aurantii Immaturus 150～165, Radix Glycyrrhizae 80～95.
The specific embodiment five: the shared parts by weight of each component are in the present embodiment: Radix Bupleuri 252, the Radix Paeoniae Alba 252, Radix Paeoniae Rubra 252, Radix Curcumae 252, Fructus Toosendan 252, Herba Lysimachiae 200, Rhizoma Corydalis 162, Cortex Moutan 126, Fructus Aurantii Immaturus 162, Radix Glycyrrhizae 90.Its preparation method is: the Radix Curcumae of 252 grams and the Rhizoma Corydalis of 162 grams are respectively got half, and it is standby to be ground into fine powder; Remaining Radix Curcumae, Rhizoma Corydalis and 252 gram Radix Bupleuri, the 252 gram Radix Paeoniae Albas, 252 gram Radix Paeoniae Rubra, 252 gram Fructus Toosendans, 200 gram Herba Lysimachiaes, 126 gram Cortex Moutans, 162 gram Fructus Aurantii Immaturuss, 90 gram Radix Glycyrrhizaes mix, decoct with water twice, adding the decocting that accounts for 10 times of amounts of all drug weight for the first time boiled 2 hours, the decocting that adds for the second time 8 times of amounts of all drug weight boiled 2 hours, collecting decoction, filter, relative density 1.10 when being concentrated into 80 ℃ slowly adds ethanol under stirring and makes determining alcohol reach 45%, leaves standstill 12 hours, get supernatant, decompression recycling ethanol, and the clear paste of the relative density 1.38～1.40 when being concentrated into 80 ℃ add Radix Curcumae, the Rhizoma Corydalis fine powder, mixing, vacuum drying is ground into fine powder, incapsulates, make 1000, promptly.
The clinical report of product treatment chronic cholecystitis of the present invention:
Chronic cholecystitis is a gallbladder chronic inflammation pathological changes.Primary disease is mostly with chronic onset, also can be by the acute cholecystitis delay that shows effect repeatedly, and the cardinal symptom of primary disease is a repeated relapsing right upper quadrant of the abdomen pain, distending pain, twinge, and omoplate portion diffuses to the right, inappetence, often increase the weight of in the feed back state of an illness, often with burning sensation in the stomach, belch is felt sick, the abdominal distention discomfort, gastral cavity abdomen feeling of fullness etc.
It is dialectical that chronic cholecystitis is pressed tcm clinical practice, and syndrome of stagnation of QI is arranged, syndrome of blood stasis, damp-heat syndrome, septicopyemia card.Product of the present invention is applicable to qi depression to blood stasis, the retention of damp-heat in the interior card, and this clinical trial phase adopts the method that compares observation with known active drug, and an evaluation is done in the curative effect and the safety of product of the present invention, now is summarized as follows;
One, physical data
From year February May to 1996 nineteen ninety-five, accept chronic cholecystitis patient 400 examples for medical treatment, be divided into treatment group and matched group at random, wherein treatment group is 300 examples, 110 of men, 190 of woman, the age is between 18～60 years old, the oldest person is 60 years old, and reckling is 25 years old, wherein 20～30 years old 45; 31～40 years old 158; 41～50 years old 75; 51～60 years old 22; Mean age is 40.6 years old.Course of disease situation is: 3 months-6 months is 108; 6 months-1 year is 79, and 1 year-1.5 years is 65, and 1.5 years-2 years is 48, and matched group is 100 examples, wherein man 38, woman 62, the age between 18～60 years old, the oldest person 58 years old, minimum is 24 years old, wherein 20～30 years old 16; 31～40 years old 52; 41～50 years old 25; 51～60 years old 7, the mean age is 41.5 years old.Course of disease situation be 3 months-6 months be 30; 6 months-1 year is 24; 1 year-1.5 years is 27; 1.5-2 year is 19.
This group case selects all to meet the traditional Chinese medical science and the up-to-date diagnostic criteria person of western medical treatment chronic cholecystitis includes the test case in, and selected case majority is the out-patient, and the minority inpatient is also arranged; Treatment group and matched group all have comparability in sex, age, state of an illness classification etc., and all case is outbreak repeatedly, and protracted course of disease is person more than 2 months.
Two, diagnostic criteria (including standard in)
Formulate following diagnostic criteria with reference to " new Chinese medicine clinical research guideline "
(1) Western medicine diagnose standard
1. upper right abdomen dull pain of persistence or sense of discomfort, or with right omoplate district pain
2. indigestion symptoms such as nauseating, belch, abdominal distention and stomach be scorching hot are arranged, the postemphasis of feed greasy food.
3. the course of disease is grown (2 months-2 years), and the state of an illness is through having acute attack and alleviating alternative characteristics.
4. there are mild tenderness and percussion pain in the gallbladder district.
5. mucus increases in the bile, and leukocyte is in heaps.
6.B super visible thickening of capsule wall of gallbladder, gallbladder dwindles or is out of shape.
(2) Chinese medical discrimination diagnostic criteria
It is dialectical that chronic cholecystitis is pressed tcm clinical practice, and syndrome of stagnation of QI is arranged, syndrome of blood stasis, and damp-heat syndrome, the septicopyemia card, product of the present invention is applicable to qi depression to blood stasis, the retention of damp-heat in the interior card, its diagnostic criteria is as follows:
1. the frequent pain of right flank or distending pain or twinge have mild tenderness, and pain is drawn the shoulder back of the body.
2. inappetence, being everlasting into, the postprandial pain feelings increase the weight of.
3. bitter taste and gluing is felt sick belch, gastral cavity abdomen feeling of fullness often.
4. pulmonary has burning sensation often.
5. the little Huang of tongue fur or little greasy, or body of the tongue is slightly dark.
6. stringy pulse or stringy and rolling pulse.
More than 1,2 indispensabilities, all the other are double sees 2, promptly diagnosable.
(3) exclusion standard
1. turn out to be acute gangrenous cholecystitis on inspection, acute obstructive suppurative cholangitis, perforation of gallbladder peritonitis etc.
2. the person that turns out to be the cholelithiasis on inspection.
3. gestation or women breast-feeding their children are to this medicine allergy sufferers under-18s or over-65s person the age.
4. be associated with cardiovascular and cerebrovascular vessel, liver, kidney and hemopoietic system serious disease and psychotic.
5. all standards of including in that do not meet, not medication in accordance with regulations can't be judged the infull person of curative effect data.
Three, observation index
(1) safety observation
1. general physical examination project;
2. blood, urine, just routine test;
3. the heart, liver, kidney function test.
(2) health giving quality is observed
1. situations such as hypochondriac pain, vomiting and nausea, belch, appetite
2. stomach is scorching hot, the abdominal distention situation
3. bitter taste situation
4. tongue fur, pulse condition
5. routine blood test, serum bilirubin detects;
6.B super the inspection.
Four. observational technique
1. treatment group: oral product of the present invention, each 4, every day 3 times
2. matched group: oral DANNING PIAN (Shanghai herbal pharmaceutical one factory's system), each 5, every day 3 times.
More than two groups all with around be a course of treatment, other all medicines of stopping using during the treatment.
Five. efficacy assessment standard:
Formulate as follows according to " new Chinese medicine clinical research guideline ":
1. clinical cure: sings and symptoms complete obiteration, ultrasound diagnosis are normal substantially.
2. produce effects: sings and symptoms disappears substantially, and ultrasound diagnosis obviously improves.
3. effective: sings and symptoms is most of to disappear, and ultrasound diagnosis has improvement.
4. invalid: sings and symptoms does not have improvement or increases the weight of, and ultrasound diagnosis does not have improvement.
Six, observed result
(1) treatment group and matched group total effects relatively see Table 1.
Table 1 treatment group and matched group total effects are relatively
| The example number | Clinical cure | Produce effects | Effectively | Invalid | Total effective rate (%) | |
| Treatment group matched group | 300 100 | 97 21 | 123 24 | 62 25 | 18 30 | 94 70 |
As known from Table 1: two groups of total effectses relatively have significant differences (P＜0.001)
Before and after (two) two groups of treatments cardinal symptom improvement situation see Table 2, table 3.
Table 2 improves situation with cardinal symptom before and after the product treatment of the present invention
| Symptom | Classification | Treat the precedent number | After the treatment | Effective percentage (%) | |||
| Disappear | Produce effects | Effectively | Invalid | ||||
| The hypochondriac pain poor appetite is vomitted and is disliked belch abdominal fullness and distention bitter taste tongue fur | + ++ +++ + ++ +++ + ++ +++ + ++ +++ + ++ +++ + ++ +++ + ++ +++ | 167 102 31 112 98 42 97 72 28 88 64 22 82 48 13 91 72 32 183 61 40 | 56 28 6 23 27 11 34 20 8 26 20 8 29 11 3 23 19 12 42 18 10 | 80 39 10 64 49 13 50 36 13 47 32 8 32 17 3 49 34 8 81 24 10 | 23 24 11 21 14 14 9 12 5 9 6 3 12 12 4 11 12 8 38 9 12 | 8 11 4 4 8 4 4 4 2 6 6 3 9 8 3 8 7 4 22 10 8 | 95.21 89.22 87.10 96.43 91.84 90.47 95.88 94.44 92.85 93.18 90.63 86.36 89.02 83.33 76.92 91.20 90.28 87.50 88.00 83.60 80.00 |
Cardinal symptom is improved situation before and after the treatment of table 3 DANNING PIAN
| Symptom | Classification | Treat the precedent number | After the treatment | Effective percentage (%) | |||
| Disappear | Produce effects | Effectively | Invalid | ||||
| The hypochondriac pain poor appetite is vomitted and is disliked belch abdominal fullness and distention bitter taste tongue fur | + ++ +++ + ++ +++ + ++ +++ + ++ +++ + ++ +++ + ++ +++ + ++ +++ | 54 35 11 35 30 14 34 25 9 40 32 10 29 20 8 31 25 12 53 22 11 | 16 8 2 9 10 4 10 8 2 11 9 2 7 4 1 8 6 3 14 5 2 | 18 12 2 13 8 3 11 5 2 13 9 3 8 5 2 10 9 3 18 6 3 | 9 6 4 7 6 4 8 6 2 8 6 2 8 5 2 8 5 3 13 6 3 | 11 9 3 6 6 3 5 6 3 8 8 3 6 6 3 5 5 3 8 5 3 | 79.63 74.29 72.73 82.85 80.00 78.57 85.29 76.00 66.67 80.00 75.00 70.00 79.31 70.00 62.50 83.87 80.00 75.00 84.90 77.27 72.73 |
(3) treatment group and matched group B ultrasonic curative effect see Table 4
Table 4 treatment group and matched group B ultrasonic curative effect are relatively
| The example number | Produce effects | Take a turn for the better | Invalid | Effective percentage (%) | |
| Treatment group matched group | 300 100 | 55 28 | 227 42 | 18 30 | 94 70 |
As can be seen from Table 4, aspect the B ultrasonic curative effect, two groups relatively have significant differences (P＜0.001)
(4) relation of patient's course of disease and curative effect sees Table 5.
The table 5 patient course of disease and therapeutic effect relationship (treatment group)
| The example number | 3～6 months | 6 months～1 year | 1～1.5 year | 1.5 year～2 years | |
| Recovery from illness produce effects enabledisable | 90 165 27 18 | 38 64 6 | 23 47 9 | 18 32 7 8 | 11 22 5 10 |
This group cure case 1 year with interior person, account for recovery from illness case 67.8%.
Seven, untoward reaction
1. this group case, take product of the present invention after, do not have any untoward reaction.
2. this group case is all carried out routine blood test, routine urinalysis, just routine, liver function, the inspection of kidney merit before and after treatment, treats the back contrast before treating and all has no adverse reaction.
Eight, observe summary:
Chronic cholecystitis is clinical very digestive disease of seeing more.Because outbreak repeatedly, protracted course of disease causes very big misery to the patient.How not satisfactory modern western modern medicine treatment is, Chinese medicine has been obtained certain curative effect in this field, and this research has been carried out the clinical contrast observation to 300 routine chronic cholecystitis patients with product of the present invention, has received comparatively satisfied curative effect, cure rate is 30%, total effective rate is 94%, and this medicine is to patient's main clinical manifestation such as flank pain, distending pain, twinge, inappetence, and the food back state of an illness increases the weight of to wait and all has clear improvement or eliminate, and its analgesic effect is particularly outstanding.Through ultrasound diagnosis: along with the disappearance of clinical symptoms, the recovery of improvement and allomeric function, gallbladder cystic fibrosis also there is reverse effect preferably, product of the present invention is to abide by motherland's theory of medicine, according to the principle of determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs and through the Chinese medicine preparation that a large amount of clinical practices is developed into, has promoting flow of QI and blood, the effect of eliminating damp-heat, for chronic cholecystitis, belong to qi depression to blood stasis, retention of damp-heat in the interior person, have curative effect preferably.
Nine, brief summary: 300 routine chronic cholecystitis patients have been observed in this research, through using product of the present invention, take a course of treatment after, cure rate is 30%, obvious effective rate is 55%, total effective rate is 94%, compares with matched group, has significant difference, (P＜0.001).
Product of the present invention has promoting flow of QI and blood, the eliminating damp-heat function, and be outstanding with its analgesic effect especially, of great advantage to removing patient disease, have no side effect, safe and reliable.
Claims (5)
1, a kind of medicine for the treatment of cholecystitis, it is characterized in that it is to be prepared from by Radix Bupleuri, the Radix Paeoniae Alba, Radix Paeoniae Rubra, Radix Curcumae, Fructus Toosendan, Herba Lysimachiae, Rhizoma Corydalis, Cortex Moutan, Fructus Aurantii Immaturus, Radix Glycyrrhizae ten flavor medicines, the shared parts by weight of each component are: Radix Bupleuri 230～270, the Radix Paeoniae Alba 230～270, Radix Paeoniae Rubra 230～270, Radix Curcumae 230～270, Fructus Toosendan 230～270, Herba Lysimachiae 180～220, Rhizoma Corydalis 140～180, Cortex Moutan 100～140, Fructus Aurantii Immaturus 140～180, Radix Glycyrrhizae 70～110.
2, the medicine of treatment cholecystitis according to claim 1 is characterized in that the shared parts by weight of each component are: Radix Bupleuri 235～265, the Radix Paeoniae Alba 235～265, Radix Paeoniae Rubra 235～265, Radix Curcumae 235～265, Fructus Toosendan 235～265, Herba Lysimachiae 185～215, Rhizoma Corydalis 145～175, Cortex Moutan 105～135, Fructus Aurantii Immaturus 145～175, Radix Glycyrrhizae 75～105.
3, the medicine of treatment cholecystitis according to claim 1 is characterized in that the shared parts by weight of each component are: Radix Bupleuri 240～260, the Radix Paeoniae Alba 240～260, Radix Paeoniae Rubra 240～260, Radix Curcumae 240～260, Fructus Toosendan 240～260, Herba Lysimachiae 190～210, Rhizoma Corydalis 140～170, Cortex Moutan 100～130, Fructus Aurantii Immaturus 140～170, Radix Glycyrrhizae 70～100.
4, the medicine of treatment cholecystitis according to claim 1 is characterized in that the shared parts by weight of each component are: Radix Bupleuri 245～255, the Radix Paeoniae Alba 245～255, Radix Paeoniae Rubra 245～255, Radix Curcumae 245～255, Fructus Toosendan 245～255, Herba Lysimachiae 195～205, Rhizoma Corydalis 150～165, Cortex Moutan 110～129, Fructus Aurantii Immaturus 150～165, Radix Glycyrrhizae 80～95.
5, the medicine of treatment cholecystitis according to claim 1 is characterized in that the shared parts by weight of each component are: Radix Bupleuri 252, the Radix Paeoniae Alba 252, Radix Paeoniae Rubra 252, Radix Curcumae 252, Fructus Toosendan 252, Herba Lysimachiae 200, Rhizoma Corydalis 162, Cortex Moutan 126, Fructus Aurantii Immaturus 162, Radix Glycyrrhizae 90.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310107689 CN1256980C (en) | 2003-11-12 | 2003-11-12 | Medicine for treating cholecystitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310107689 CN1256980C (en) | 2003-11-12 | 2003-11-12 | Medicine for treating cholecystitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1615916A CN1615916A (en) | 2005-05-18 |
| CN1256980C true CN1256980C (en) | 2006-05-24 |
Family
ID=34758340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200310107689 Expired - Lifetime CN1256980C (en) | 2003-11-12 | 2003-11-12 | Medicine for treating cholecystitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1256980C (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101279083B (en) * | 2008-05-15 | 2010-07-28 | 包瑞 | Chinese medicine preparation for curing acute or chronic cholecystitis and method of preparing the same |
| CN102125677B (en) * | 2010-10-27 | 2012-05-09 | 宋爱民 | Chinese medicine preparation for treating acute cholecystitia |
| CN103520627B (en) * | 2013-10-15 | 2015-04-29 | 张东兰 | Traditional Chinese medicine for treating hypochondriac pain with syndrome type of irascibility exuberant |
| CN114767635A (en) * | 2022-04-07 | 2022-07-22 | 兰州岐伯中医研究院 | Gallbladder-pancreas granule and its preparation method |
-
2003
- 2003-11-12 CN CN 200310107689 patent/CN1256980C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1615916A (en) | 2005-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101028507A (en) | Chinese-medicinal composition for treating asthma | |
| CN101041033A (en) | Chinese medicine for treating hepatitis B | |
| CN104225441A (en) | Traditional Chinese medicine composition for treating stomach trouble and preparation method of granules and capsules of traditional Chinese medicine composition | |
| CN103520680A (en) | Traditional Chinese medicine for treating acute heart failure | |
| CN1183919C (en) | Cancer treating medical composition | |
| CN100493586C (en) | Oral liquid for treating breast cancer, liver cancer or lung caner, and preparation thereof | |
| CN1152707C (en) | pill for treating diarrhea | |
| CN104225319A (en) | Traditional Chinese preparation for treating acute renal failure | |
| CN1256980C (en) | Medicine for treating cholecystitis | |
| CN1218721C (en) | Chinese medicine proprietary for treating cerebrovascular and cardiovascular disease | |
| CN1285380C (en) | Chinese patent medicines for treating chronic superficial gastritis (epigastric pain) and preparation method thereof | |
| CN1234390C (en) | Medicine for treating hydrops and hydroncus and preparing method thereof | |
| CN1481870A (en) | Compound traditional Chinese medicine preparation for treating intractable chronic constipation and preparation method thereof | |
| CN1903347A (en) | Medicine composition for treating alimentary canal diseases, prepn. method and application thereof | |
| CN101057945A (en) | Traditional Chinese medicine for treating digestive cancer and its producing method | |
| CN1187064C (en) | Medicine for treating epidemic hemorrhagic fever | |
| CN114732883B (en) | Traditional Chinese medicine composition for strengthening spleen and tonifying stomach as well as preparation method and application thereof | |
| CN113274470B (en) | Traditional Chinese medicine composition for treating novel coronavirus pneumonia | |
| CN1059574C (en) | Chinese medicine preparation | |
| CN1241633C (en) | Snake venom capsule for treating lymph cancer and its preparation method | |
| CN1194717C (en) | Snake poison capsule for treating lung cancer and its preparation method | |
| CN1299752C (en) | Traditional Chinese medicine capsule for treating urinary calculus and its prepn. method | |
| CN1785358A (en) | Medicine for treating acne and its preparation method | |
| CN1050297C (en) | Chinese herbal medicine composition for preparing non-dependence anti-cancer pain-alleviating drug and preparation thereof | |
| CN1259960C (en) | Medication for curing stomach trouble and disease of bills and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20211027 Address after: 570100 plot b0625-1, mei'an science and technology new town, national high tech Industrial Development Zone, Haikou City, Hainan Province Patentee after: Letai Pharmaceutical (Hainan) Co.,Ltd. Address before: 150025, Harbin City, Heilongjiang Province Economic and Technological Development Zone in the middle of Beijing Road, Harbin Thai Thai Pharmaceutical Co., Ltd. Patentee before: Lang Weijun |
|
| TR01 | Transfer of patent right | ||
| CX01 | Expiry of patent term |
Granted publication date: 20060524 |
|
| CX01 | Expiry of patent term |